These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 28338115)

  • 1. Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.
    Elgebaly A; Radwan IA; AboElnas MM; Ibrahim HH; Eltoomy MF; Atta AA; Mesalam HA; Sayed AA; Othman AA
    J Gastrointestin Liver Dis; 2017 Mar; 26(1):59-67. PubMed ID: 28338115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.
    Zhang C; Yuan W; Fang J; Wang W; He P; Lei J; Wang C
    PLoS One; 2016; 11(8):e0161792. PubMed ID: 27560482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Wei Z; Liu N; Tantai X; Xing X; Xiao C; Chen L; Wang J
    Hepatol Int; 2019 May; 13(3):302-313. PubMed ID: 30446932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of curcumin supplementation on liver function, metabolic profile and body composition in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Mahmoodi M; Mosallanezhad Z; Jalali R; Imanieh MH; Moosavian SP
    Complement Ther Med; 2020 Jan; 48():102283. PubMed ID: 31987259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Wang LL; Zhang PH; Yan HH
    Front Nutr; 2023; 10():1014010. PubMed ID: 36866059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
    Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
    Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
    Guo XF; Yang B; Tang J; Li D
    Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Wei S; Yu X
    Complement Ther Med; 2021 Mar; 57():102635. PubMed ID: 33271299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials.
    Rafiee S; Mohammadi H; Ghavami A; Sadeghi E; Safari Z; Askari G
    Complement Ther Clin Pract; 2021 Feb; 42():101281. PubMed ID: 33321448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Combined Vitamin E and C for Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Poonyam P; Kritsanaviparkporn C; Chommaitree P; Soodcharoen A
    Asian Pac J Cancer Prev; 2022 Sep; 23(9):2891-2899. PubMed ID: 36172650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials.
    Zeraattalab-Motlagh S; Jayedi A; Shab-Bidar S
    Am J Clin Nutr; 2021 Nov; 114(5):1675-1685. PubMed ID: 34320173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis.
    Jakubczyk K; Skonieczna-Żydecka K; Kałduńska J; Stachowska E; Gutowska I; Janda K
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
    Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
    Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
    Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
    Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
    Heebøll S; Kreuzfeldt M; Hamilton-Dutoit S; Kjær Poulsen M; Stødkilde-Jørgensen H; Møller HJ; Jessen N; Thorsen K; Kristina Hellberg Y; Bønløkke Pedersen S; Grønbæk H
    Scand J Gastroenterol; 2016; 51(4):456-64. PubMed ID: 26784973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease.
    Tejada S; Capó X; Mascaró CM; Monserrat-Mesquida M; Quetglas-Llabrés MM; Pons A; Tur JA; Sureda A
    Curr Pharm Des; 2021; 27(22):2558-2570. PubMed ID: 32303170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.